Abstract
Glioblastoma is highly resistant to radiation therapy. The underlying molecular mechanism is not completely understood. The DNA damage response (DDR) pathway plays a crucial role in radioresistance of glioablastoma cells. Growing evidence has demonstrated that radiation induces alterations in microRNA (miR) profiles. However, how radiation induces specific miRs and how they might regulate the DDR remain elusive. In our study, we found that radiation induced c-jun transcription of miR-221 and miR-222. miR-221 and miR- 222 modulated DNA-PKcs expression to affect DNA damage repair by activating Akt independent of PTEN status. Knocking down of miR-221/222 significantly increased radiosensitivity of glioblastoma cells. Inhibition of Akt by RNAi or LY294002 treatment may overcome miR-221/222 induced radioresistance. Notably, combined anti-miR-221/222 and radiotherapy has remarkably inhibited tumor growth compared with anti-miR-221/222 or radiotherapy alone in a subcutaneous mouse model. Our results suggest that radio-induced c-jun promotes transcription of miR-221/222, which mediates DNA damage repair of glioblastoma cells independent of PTEN. These data indicate for the first time that miR-221/222 play an important role in mediating radio-induced DNA damage repair and that miR-221/222 could serve as potential therapeutic targets for increasing radiosensitivity of glioblastoma cells.
Keywords: Glioblastoma, radiosensitivity, miR-221, DDR, Akt.
Current Molecular Medicine
Title:miR-221/222 Confers Radioresistance in Glioblastoma Cells Through Activating Akt Independent of PTEN Status
Volume: 14 Issue: 1
Author(s): W. Li, F. Guo, P. Wang, S. Hong and C. Zhang
Affiliation:
Keywords: Glioblastoma, radiosensitivity, miR-221, DDR, Akt.
Abstract: Glioblastoma is highly resistant to radiation therapy. The underlying molecular mechanism is not completely understood. The DNA damage response (DDR) pathway plays a crucial role in radioresistance of glioablastoma cells. Growing evidence has demonstrated that radiation induces alterations in microRNA (miR) profiles. However, how radiation induces specific miRs and how they might regulate the DDR remain elusive. In our study, we found that radiation induced c-jun transcription of miR-221 and miR-222. miR-221 and miR- 222 modulated DNA-PKcs expression to affect DNA damage repair by activating Akt independent of PTEN status. Knocking down of miR-221/222 significantly increased radiosensitivity of glioblastoma cells. Inhibition of Akt by RNAi or LY294002 treatment may overcome miR-221/222 induced radioresistance. Notably, combined anti-miR-221/222 and radiotherapy has remarkably inhibited tumor growth compared with anti-miR-221/222 or radiotherapy alone in a subcutaneous mouse model. Our results suggest that radio-induced c-jun promotes transcription of miR-221/222, which mediates DNA damage repair of glioblastoma cells independent of PTEN. These data indicate for the first time that miR-221/222 play an important role in mediating radio-induced DNA damage repair and that miR-221/222 could serve as potential therapeutic targets for increasing radiosensitivity of glioblastoma cells.
Export Options
About this article
Cite this article as:
Li W., Guo F., Wang P., Hong S. and Zhang C., miR-221/222 Confers Radioresistance in Glioblastoma Cells Through Activating Akt Independent of PTEN Status, Current Molecular Medicine 2014; 14 (1) . https://dx.doi.org/10.2174/1566524013666131203103147
DOI https://dx.doi.org/10.2174/1566524013666131203103147 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders
Vertigo and vestibular diseases are common among middle-aged and older adults, significantly increasing the risk of falls and leading to injuries and disabilities. Despite their prevalence, therapeutic advancements are hindered by a limited understanding of the underlying molecular and cellular mechanisms. This Special Issue is dedicated to bridging this gap ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Erlotinib in Glioblastoma - Lost in Translation?
Anti-Cancer Agents in Medicinal Chemistry Transient Hepatotoxicity Induced by Vinblastine in a Young Girl with Chiasmatic Low Grade Glioma
Current Drug Safety MicroRNAs in Glioblastoma: Role in Pathogenesis and Opportunities for Targeted Therapies
CNS & Neurological Disorders - Drug Targets Ceramide-Based Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Editorial (BIOQUEST India: A Global Biotechnology Forum for Knowledge-Based Innovation and Sustainable Development)
Current Pharmacogenomics and Personalized Medicine Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments
Mini-Reviews in Medicinal Chemistry Structure-Function Relationships in the Interaction Between the Urokinase- Type Plasminogen Activator and Its Receptor
Current Pharmaceutical Design Perspectives of Plant Natural Products in Inhibition of Cancer Invasion and Metastasis by Regulating Multiple Signaling Pathways
Current Medicinal Chemistry Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry Luminescent Silica Nanoparticles for Cancer Diagnosis
Current Medicinal Chemistry Chemotherapeutic Effects of Boswellic Acid Against Human Glioblastoma Multiform: A Comprehensive Review
The Natural Products Journal Circulating MicroRNAs as Potential Biomarkers in Glioma: A Mini-Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Heparanase: Structure, Biological Functions, and Inhibition by Heparin-Derived Mimetics of Heparan Sulfate
Current Pharmaceutical Design Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets Gold Nanoparticle-Based Drug Delivery Platform for Antineoplastic Chemotherapy
Current Drug Metabolism Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging The Potential Roles of Magnetic Resonance Spectroscopy and Perfusion- Weighted Imaging in the Grading of Cerebral Gliomas
Current Medical Imaging The Microarray Gene Profiling Analysis of Glioblastoma Cancer Cells Reveals Genes Affected by FAK Inhibitor Y15 and Combination of Y15 and Temozolomide
Anti-Cancer Agents in Medicinal Chemistry Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets